In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda's Global Ambition

Executive Summary

Takeda Pharmaceutical's drug business started out manufacturing and selling bismuth-the basic ingredient in Pepto-Bismol--in 1895. A century later, it's still chained to the stomach-settling game with Prevacid, a $1.4 billion drug whose patent will expire in 2009, taking with it a huge percentage of Takeda's earnings. That's one big reason why Japan's largest and most international pharmaceutical company is on a US-focused dealmaking tear. Since February, Takeda has inked three major licensing partnerships and completed the largest acquisition in its history in a desperate attempt to shore up a thin pipeline.

Related Content

With Nycomed, Takeda Satifies Both Strategic And Financial Objectives
Astellas Wins OSI But Victory Comes At A Price
Millennium Prospers Under Takeda--But Will Takeda Get Full Value?
Bristol-Myers Squibb and Otsuka Stabilize Their Bases
GSK Tries to Mimic Real-World Biotech
Pfizer's Increasingly Specialist Focus
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2008
Alnylam Takes Platform Monetization to a Whole New and Non-Exclusive Level
Reviewing Five Years of Big Pharma's Biotech Acquisitions
Takeda Comes to America

Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts